ClearPoint Neuro, Inc. (NASDAQ:CLPT) Expected to Post Q2 2024 Earnings of ($0.18) Per Share

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Research analysts at B. Riley issued their Q2 2024 EPS estimates for shares of ClearPoint Neuro in a note issued to investors on Wednesday, July 24th. B. Riley analyst K. Bauser anticipates that the company will earn ($0.18) per share for the quarter. B. Riley has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.70) EPS and FY2025 earnings at ($0.59) EPS.

ClearPoint Neuro Price Performance

Shares of ClearPoint Neuro stock opened at $7.21 on Monday. The company has a 50-day moving average of $6.14 and a 200 day moving average of $6.43. The firm has a market cap of $197.70 million, a price-to-earnings ratio of -8.58 and a beta of 1.08. ClearPoint Neuro has a 1 year low of $4.05 and a 1 year high of $7.97.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Tuesday, May 7th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. ClearPoint Neuro had a negative net margin of 78.84% and a negative return on equity of 76.92%. The firm had revenue of $7.64 million during the quarter, compared to analysts’ expectations of $7.04 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of ClearPoint Neuro by 7.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company’s stock worth $170,000 after acquiring an additional 1,813 shares in the last quarter. Lane Generational LLC increased its stake in ClearPoint Neuro by 16.4% during the 4th quarter. Lane Generational LLC now owns 174,291 shares of the company’s stock valued at $1,183,000 after purchasing an additional 24,512 shares in the last quarter. Legato Capital Management LLC increased its stake in ClearPoint Neuro by 21.6% during the 2nd quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock valued at $857,000 after purchasing an additional 28,227 shares in the last quarter. Cahill Wealth Management LLC increased its stake in ClearPoint Neuro by 23.5% during the 4th quarter. Cahill Wealth Management LLC now owns 232,263 shares of the company’s stock valued at $1,577,000 after purchasing an additional 44,179 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of ClearPoint Neuro by 23,048.0% in the first quarter. Russell Investments Group Ltd. now owns 46,296 shares of the company’s stock worth $315,000 after acquiring an additional 46,096 shares during the period. 30.08% of the stock is currently owned by institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.